The Experts below are selected from a list of 42 Experts worldwide ranked by ideXlab platform

Antoni J Duleba - One of the best experts on this subject based on the ideXlab platform.

  • effects of simvastatin and Oral Contraceptive Agent on polycystic ovary syndrome prospective randomized crossover trial
    Obstetrical & Gynecological Survey, 2007
    Co-Authors: Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba
    Abstract:

    There is increasing evidence that statins improve the lipid profile and also have cardioprotective effects that include an anti-inflammatory action and improved endothelial dysfunction. Preliminary findings from a 12-week trial suggest that women with polycystic ovary syndrome (PCOS) had lower total testosterone levels and a better lipid profile when given simvastatin plus an Oral Contraceptive pill (OCP) rather than an OCP alone. The final results of this trial, after a crossover of treatments and follow-up for 24 weeks, now are available. The 48 women entered into the study were prospectively randomized to receive simvastatin plus OCP for 12 weeks followed by OCP alone for 12 weeks longer, or OCP alone for 12 weeks and then combined treatment. Simvastatin was given Orally in a daily dose of 20 mg. The OCP contained 20 μg of ethinyl estradiol and 150 μg of desogestrelpo. Total serum testosterone declined 38% after combined treatment but only by 26% with OC alone, a highly significant difference. The corresponding figures for free testosterone levels were 58% and 35%. Hirsutism decreased by about 8% with combined treatment and by less than 5% with OCP treatment; this difference also was significant. Similar effects on levels of dehydroepiandrosterone sulfate accompanied the two treatment regimens. Simvastatin therapy correlated with decreased levels of luteinizing hormone, but no changes in follicle-stimulating hormone or prolactin. Total cholesterol decreased by 7.5% with combined treatment but increased modestly on OCP alone. Both treatments were associated with increases in high-density lipoprotein cholesterol. With combined treatment, low-density lipoprotein cholesterol decreased by 20%. Triglycerides did not change with combined treatment but rose by one-fifth on OCP alone. OCP treatment led to a modest but significant negative effect on glucose metabolism. Both combined treatment and OCP correlated with a significant increase in fasting insulin. Statin therapy significantly improved markers of systemic inflammation including high-sensitivity C-reactive protein and soluble vascular cell adhesion molecule. No significant changes in body mass index were noted, and none of the subjects developed symptoms of muscle damage or biochemical evidence of liver dysfunction. These findings show that simvastatin therapy can substantially lessen clinical and endocrinological elements of PCOS and, at the same time, decrease cardiovascular risk factors.

  • effects of simvastatin and Oral Contraceptive Agent on polycystic ovary syndrome prospective randomized crossover trial
    The Journal of Clinical Endocrinology and Metabolism, 2007
    Co-Authors: Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba
    Abstract:

    Context: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and cardiovascular risks including dyslipidemia and systemic inflammation. In vitro, statins decrease proliferation and steroidogenesis of ovarian theca-interstitial cells. Objective: The study objective was to compare effects of two treatments of PCOS: simvastatin plus Oral Contraceptive pill (OCP) vs. OCP alone. Design: In a prospective, crossover trial, 48 women with PCOS were randomized to either simvastatin plus OCP for 12 wk followed by OCP alone for an additional 12 wk, or to OCP alone for 12 wk and, subsequently, simvastatin plus OCP for an additional 12 wk. Evaluations were performed at baseline, after 12 wk (crossover), and after 24 wk. Data were analyzed using a random effects model. Setting: The study was conducted in an academic medical center. Primary Outcome: Serum total testosterone was the primary outcome measure. Results: Total testosterone decreased by 38% after Statin + OCP, whereas OCP alone led to a 26% dec...

Vigfus Sigurdsson - One of the best experts on this subject based on the ideXlab platform.

  • selecting an Oral Contraceptive Agent for the treatment of acne in women
    American Journal of Clinical Dermatology, 2004
    Co-Authors: Willem A Van Vloten, Vigfus Sigurdsson
    Abstract:

    In women, acne can be successfully treated with Oral Contraceptives. This article focuses on the results of clinical studies on the treatment of acne with Oral Contraceptives. From the literature, 12 such studies could be traced over the last 10 years. Most of the studies were multicenter, randomized, and double blind. Five studies were placebo controlled. All of these studies were analyzed and compared with each other. Statistically, all placebo-controlled studies showed a better result with the active treatment, than with the placebo. However, the placebo groups also showed an improvement in the acne lesions. In seven studies, two Oral Contraceptives were compared for their effect on acne vulgaris. All Oral Contraceptives studied showed a beneficial effect on the severity of acne.

Beata Banaszewska - One of the best experts on this subject based on the ideXlab platform.

  • effects of simvastatin and Oral Contraceptive Agent on polycystic ovary syndrome prospective randomized crossover trial
    Obstetrical & Gynecological Survey, 2007
    Co-Authors: Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba
    Abstract:

    There is increasing evidence that statins improve the lipid profile and also have cardioprotective effects that include an anti-inflammatory action and improved endothelial dysfunction. Preliminary findings from a 12-week trial suggest that women with polycystic ovary syndrome (PCOS) had lower total testosterone levels and a better lipid profile when given simvastatin plus an Oral Contraceptive pill (OCP) rather than an OCP alone. The final results of this trial, after a crossover of treatments and follow-up for 24 weeks, now are available. The 48 women entered into the study were prospectively randomized to receive simvastatin plus OCP for 12 weeks followed by OCP alone for 12 weeks longer, or OCP alone for 12 weeks and then combined treatment. Simvastatin was given Orally in a daily dose of 20 mg. The OCP contained 20 μg of ethinyl estradiol and 150 μg of desogestrelpo. Total serum testosterone declined 38% after combined treatment but only by 26% with OC alone, a highly significant difference. The corresponding figures for free testosterone levels were 58% and 35%. Hirsutism decreased by about 8% with combined treatment and by less than 5% with OCP treatment; this difference also was significant. Similar effects on levels of dehydroepiandrosterone sulfate accompanied the two treatment regimens. Simvastatin therapy correlated with decreased levels of luteinizing hormone, but no changes in follicle-stimulating hormone or prolactin. Total cholesterol decreased by 7.5% with combined treatment but increased modestly on OCP alone. Both treatments were associated with increases in high-density lipoprotein cholesterol. With combined treatment, low-density lipoprotein cholesterol decreased by 20%. Triglycerides did not change with combined treatment but rose by one-fifth on OCP alone. OCP treatment led to a modest but significant negative effect on glucose metabolism. Both combined treatment and OCP correlated with a significant increase in fasting insulin. Statin therapy significantly improved markers of systemic inflammation including high-sensitivity C-reactive protein and soluble vascular cell adhesion molecule. No significant changes in body mass index were noted, and none of the subjects developed symptoms of muscle damage or biochemical evidence of liver dysfunction. These findings show that simvastatin therapy can substantially lessen clinical and endocrinological elements of PCOS and, at the same time, decrease cardiovascular risk factors.

  • effects of simvastatin and Oral Contraceptive Agent on polycystic ovary syndrome prospective randomized crossover trial
    The Journal of Clinical Endocrinology and Metabolism, 2007
    Co-Authors: Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba
    Abstract:

    Context: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and cardiovascular risks including dyslipidemia and systemic inflammation. In vitro, statins decrease proliferation and steroidogenesis of ovarian theca-interstitial cells. Objective: The study objective was to compare effects of two treatments of PCOS: simvastatin plus Oral Contraceptive pill (OCP) vs. OCP alone. Design: In a prospective, crossover trial, 48 women with PCOS were randomized to either simvastatin plus OCP for 12 wk followed by OCP alone for an additional 12 wk, or to OCP alone for 12 wk and, subsequently, simvastatin plus OCP for an additional 12 wk. Evaluations were performed at baseline, after 12 wk (crossover), and after 24 wk. Data were analyzed using a random effects model. Setting: The study was conducted in an academic medical center. Primary Outcome: Serum total testosterone was the primary outcome measure. Results: Total testosterone decreased by 38% after Statin + OCP, whereas OCP alone led to a 26% dec...

Willem A Van Vloten - One of the best experts on this subject based on the ideXlab platform.

  • selecting an Oral Contraceptive Agent for the treatment of acne in women
    American Journal of Clinical Dermatology, 2004
    Co-Authors: Willem A Van Vloten, Vigfus Sigurdsson
    Abstract:

    In women, acne can be successfully treated with Oral Contraceptives. This article focuses on the results of clinical studies on the treatment of acne with Oral Contraceptives. From the literature, 12 such studies could be traced over the last 10 years. Most of the studies were multicenter, randomized, and double blind. Five studies were placebo controlled. All of these studies were analyzed and compared with each other. Statistically, all placebo-controlled studies showed a better result with the active treatment, than with the placebo. However, the placebo groups also showed an improvement in the acne lesions. In seven studies, two Oral Contraceptives were compared for their effect on acne vulgaris. All Oral Contraceptives studied showed a beneficial effect on the severity of acne.

James Dziura - One of the best experts on this subject based on the ideXlab platform.

  • effects of simvastatin and Oral Contraceptive Agent on polycystic ovary syndrome prospective randomized crossover trial
    Obstetrical & Gynecological Survey, 2007
    Co-Authors: Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba
    Abstract:

    There is increasing evidence that statins improve the lipid profile and also have cardioprotective effects that include an anti-inflammatory action and improved endothelial dysfunction. Preliminary findings from a 12-week trial suggest that women with polycystic ovary syndrome (PCOS) had lower total testosterone levels and a better lipid profile when given simvastatin plus an Oral Contraceptive pill (OCP) rather than an OCP alone. The final results of this trial, after a crossover of treatments and follow-up for 24 weeks, now are available. The 48 women entered into the study were prospectively randomized to receive simvastatin plus OCP for 12 weeks followed by OCP alone for 12 weeks longer, or OCP alone for 12 weeks and then combined treatment. Simvastatin was given Orally in a daily dose of 20 mg. The OCP contained 20 μg of ethinyl estradiol and 150 μg of desogestrelpo. Total serum testosterone declined 38% after combined treatment but only by 26% with OC alone, a highly significant difference. The corresponding figures for free testosterone levels were 58% and 35%. Hirsutism decreased by about 8% with combined treatment and by less than 5% with OCP treatment; this difference also was significant. Similar effects on levels of dehydroepiandrosterone sulfate accompanied the two treatment regimens. Simvastatin therapy correlated with decreased levels of luteinizing hormone, but no changes in follicle-stimulating hormone or prolactin. Total cholesterol decreased by 7.5% with combined treatment but increased modestly on OCP alone. Both treatments were associated with increases in high-density lipoprotein cholesterol. With combined treatment, low-density lipoprotein cholesterol decreased by 20%. Triglycerides did not change with combined treatment but rose by one-fifth on OCP alone. OCP treatment led to a modest but significant negative effect on glucose metabolism. Both combined treatment and OCP correlated with a significant increase in fasting insulin. Statin therapy significantly improved markers of systemic inflammation including high-sensitivity C-reactive protein and soluble vascular cell adhesion molecule. No significant changes in body mass index were noted, and none of the subjects developed symptoms of muscle damage or biochemical evidence of liver dysfunction. These findings show that simvastatin therapy can substantially lessen clinical and endocrinological elements of PCOS and, at the same time, decrease cardiovascular risk factors.

  • effects of simvastatin and Oral Contraceptive Agent on polycystic ovary syndrome prospective randomized crossover trial
    The Journal of Clinical Endocrinology and Metabolism, 2007
    Co-Authors: Beata Banaszewska, Leszek Pawelczyk, Robert Z Spaczynski, James Dziura, Antoni J Duleba
    Abstract:

    Context: Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and cardiovascular risks including dyslipidemia and systemic inflammation. In vitro, statins decrease proliferation and steroidogenesis of ovarian theca-interstitial cells. Objective: The study objective was to compare effects of two treatments of PCOS: simvastatin plus Oral Contraceptive pill (OCP) vs. OCP alone. Design: In a prospective, crossover trial, 48 women with PCOS were randomized to either simvastatin plus OCP for 12 wk followed by OCP alone for an additional 12 wk, or to OCP alone for 12 wk and, subsequently, simvastatin plus OCP for an additional 12 wk. Evaluations were performed at baseline, after 12 wk (crossover), and after 24 wk. Data were analyzed using a random effects model. Setting: The study was conducted in an academic medical center. Primary Outcome: Serum total testosterone was the primary outcome measure. Results: Total testosterone decreased by 38% after Statin + OCP, whereas OCP alone led to a 26% dec...